S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Strange Money Secret Used by the Ultra-Wealthy (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Strange Money Secret Used by the Ultra-Wealthy (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Strange Money Secret Used by the Ultra-Wealthy (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Strange Money Secret Used by the Ultra-Wealthy (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

$24.00
+0.45 (+1.91%)
(As of 03/1/2024 ET)
Today's Range
$23.46
$24.54
50-Day Range
$22.18
$29.10
52-Week Range
$19.52
$30.52
Volume
673,051 shs
Average Volume
639,274 shs
Market Capitalization
$1.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Veracyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
25.0% Upside
$30.00 Price Target
Short Interest
Healthy
3.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
0.71mentions of Veracyte in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to ($0.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

Medical Sector

414th out of 952 stocks

Medical Laboratories Industry

11th out of 20 stocks


VCYT stock logo

About Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock Price History

VCYT Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Veracyte (NASDAQ:VCYT) Shares Down 7.3%
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Veracyte (NASDAQ:VCYT) Rating Reiterated by William Blair
Recap: Veracyte Q4 Earnings
VCYT Mar 2024 35.000 put
VCYT Mar 2024 20.000 put
Veracyte Completes Acquisition of C2i Genomics
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VCYT
Employees
787
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$34.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-74,400,000.00
Pretax Margin
-14.45%

Debt

Sales & Book Value

Annual Sales
$361.05 million
Book Value
$14.98 per share

Miscellaneous

Free Float
71,141,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
1.68

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 54)
    CEO & Director
    Comp: $1.25M
  • Ms. Rebecca ChambersMs. Rebecca Chambers (Age 46)
    Executive VP & CFO
    Comp: $772.41k
  • Ms. Annie McGuire (Age 43)
    Executive VP, General Counsel & Chief People Officer
    Comp: $633.65k
  • Mr. Jonathan Wygant (Age 53)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Senior VP & Chief Information Officer
  • Dr. Phillip G. Febbo M.D. (Age 58)
    Chief Scientific & Medical Officer
  • Ms. Karen Possemato
    Senior Vice President of Corporate Marketing, Communications & Commercial Operations
  • Mr. Robert Brainin (Age 53)
    Executive VP & Chief Business Officer
  • Dr. John Leite Ph.D.
    Chief Commercial Officer for CLIA Business
  • Ms. Corinne Danan
    Senior VP and GM of Biopharma & IVD Services














VCYT Stock Analysis - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price target for 2024?

5 Wall Street analysts have issued 12-month price targets for Veracyte's stock. Their VCYT share price targets range from $21.00 to $34.00. On average, they predict the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2024?

Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT shares have decreased by 12.8% and is now trading at $24.00.
View the best growth stocks for 2024 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The biotechnology company had revenue of $90.32 million for the quarter, compared to analyst estimates of $83.05 million. Veracyte had a negative trailing twelve-month return on equity of 2.01% and a negative net margin of 20.61%. Veracyte's quarterly revenue was up 24.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.48%), Vanguard Group Inc. (9.75%), Dimensional Fund Advisors LP (4.62%), Artisan Partners Limited Partnership (4.41%), Sumitomo Mitsui Trust Holdings Inc. (4.25%) and Nikko Asset Management Americas Inc. (4.25%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
This page (NASDAQ:VCYT) was last updated on 3/2/2024 by MarketBeat.com Staff